title: Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.
abstract: For patients with newly diagnosed hypertension, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are usually the first-line therapies. There is, however, no real-life data regarding the relative clinical effectiveness and tolerability of either drug class. The prospective registry, Treatment With Azilsartan Compared to ACE Inhibitors in Antihypertensive Therapy (EARLY), was conducted to evaluate the effectiveness of the ARB azilsartan medoxomil (AZL-M) vs ACE inhibitors in real-world patients. Of the 1153 patients with newly diagnosed hypertension who were included in the registry, 789 were prescribed AZL-M and 364 were prescribed an ACE inhibitor. After multivariate adjustment, AZL-M was found to provide superior blood pressure reduction and better target blood pressure (<140/90 mm Hg) achievement. The proportion of patients with adverse events was not statistically different between groups. The authors conclude that in newly diagnosed hypertensive patients, AZL-M provides superior blood pressure control with a similar safety profile compared with ACE inhibitors.
authors.affiliation: Universitätsklinikum Erlangen, Medizinische Klinik 4, Schwerpunkt Nephrologie/Hypertensiologie, Erlangen, Germany.
authors.forename: Roland E
authors.initials: RE
authors.lastname: Schmieder
authors.affiliation: Universitätsklinikum Düsseldorf, Klinik für Nephrologie, Düsseldorf, Germany.
authors.forename: Sebastian A
authors.initials: SA
authors.lastname: Potthoff
authors.affiliation: Institut für Pharmakologie und präventive Medizin, Mahlow, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Bramlage
authors.affiliation: Clemens-Hospital Münster, Klinik für Innere Medizin I, Münster, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Baumgart
authors.affiliation: Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Mahfoud
authors.affiliation: MedCommTools, Medical-Scientific Consultancy, Hannover, Germany.
authors.forename: Hartmut
authors.initials: H
authors.lastname: Buhck
authors.affiliation: Institut für Herzinfarktforschung GmbH, Ludwigshafen, Germany.
authors.forename: Taoufik
authors.initials: T
authors.lastname: Ouarrak
authors.affiliation: Takeda Pharma, Berlin, Deutschland.
authors.forename: Martina
authors.initials: M
authors.lastname: Ehmen
authors.affiliation: Institut für Herzinfarktforschung GmbH, Ludwigshafen, Germany.
authors.forename: Jochen
authors.initials: J
authors.lastname: Senges
authors.affiliation: Institut für Herzinfarktforschung GmbH, Ludwigshafen, Germany.|Herzzentrum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany.
authors.forename: Anselm K
authors.initials: AK
authors.lastname: Gitt
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001795:Blood Pressure Determination / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010069:Oxadiazoles / Q000008:administration & dosage* / Q000494:pharmacology; D011446:Prospective Studies; D017257:Ramipril / Q000008:administration & dosage*; D012042:Registries
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D010069:Oxadiazoles; C521273:azilsartan; D017257:Ramipril; C557413:azilsartan medoxomil